What Is the Latest Treatment for Enlarged Prostate?

The treatment landscape for enlarged prostate, clinically known as benign prostatic hyperplasia (BPH), has expanded dramatically over the past decade. While daily pills and traditional surgery remain options, the biggest shift has been toward minimally invasive procedures that can be done in an outpatient setting, preserve sexual function, and still deliver meaningful symptom relief. Treatments like water vapor thermal therapy (Rezūm), the prostatic urethral lift (UroLift), and robotic waterjet ablation (Aquablation) represent the newest wave, though deciding which is “best” depends heavily on prostate size, symptom severity, and what trade-offs matter most to you.

Why the Prostate Causes Trouble in the First Place

The prostate grows throughout a man’s life under the influence of hormones, particularly dihydrotestosterone (DHT). DHT drives prostate cell growth during normal development, but in adulthood it can fuel pathologic enlargement that squeezes the urethra and makes urination progressively harder.¹ That squeeze is what produces the familiar symptoms: a weak stream, frequent nighttime trips to the bathroom, the feeling that your bladder never fully empties, and in severe cases, complete inability to urinate at all. Roughly half of men in their fifties and the majority of men over seventy have some degree of BPH, though not all experience bothersome symptoms.

Medications That Are Still the First Line

Most men with mild to moderate symptoms start with medication. Two main drug classes tackle BPH from different angles, and newer guidelines increasingly recommend using them together for men with larger prostates or more severe symptoms.

Alpha Blockers

Alpha blockers like tamsulosin and doxazosin relax the smooth muscle around the prostate and bladder neck. They work fast, often producing noticeable symptom relief within days. The downside is that they don’t shrink the prostate or change the long-term risk of needing surgery or developing urinary retention.² Common side effects include dizziness, low blood pressure when standing, and ejaculatory problems.

5-Alpha Reductase Inhibitors

Drugs like finasteride and dutasteride block the conversion of testosterone to DHT, which gradually shrinks the prostate over months. Unlike alpha blockers, these medications do reduce the long-term risk of urinary retention and the eventual need for surgery, but they take three to six months to show full effect and can cause sexual side effects including reduced libido and erectile difficulties.

Combination Therapy

Using an alpha blocker and a 5-alpha reductase inhibitor together has become a standard approach for men with larger prostates and higher symptom scores. The landmark MTOPS trial, which followed over 3,400 men for an average of four and a half years, found that combining doxazosin and finasteride reduced the risk of clinical progression by about two-thirds compared to placebo, substantially more than either drug alone.³ In that trial, only the finasteride-containing arms reduced the risk of urinary retention and the need for invasive treatment. A meta-analysis looking specifically at tamsulosin plus dutasteride confirmed that the combination produced better symptom scores, smaller prostate volume, and a lower rate of clinical progression than tamsulosin alone.⁴ Combination therapy makes the most sense for men with larger prostates (typically above 30 to 40 grams), higher PSA levels, and moderate to severe symptoms.⁵

Tadalafil

Daily low-dose tadalafil, the same drug used for erectile dysfunction, was approved for BPH symptoms and has carved out a niche for men who have both conditions. A randomized trial found that 5 mg daily produced a clinically meaningful improvement in symptom scores as early as one week, reaching statistical significance by four weeks.⁶ The catch is that tadalafil doesn’t improve urinary flow rate or post-void residual volume in most studies, so it’s better at easing the subjective feeling of symptoms than at physically improving how the bladder empties.⁷ If your main complaint is frequent urgency and quality of life rather than a severely weak stream, tadalafil is worth discussing with your doctor.

Where Surgery Still Fits

For decades, transurethral resection of the prostate (TURP) has been the benchmark surgical treatment. A surgeon threads an instrument through the urethra and shaves away excess prostate tissue. It remains effective, but it carries real trade-offs: a study grading complications found an overall complication rate of about 29%, though the vast majority were mild to moderate and manageable with conservative treatment or minor procedures.⁸ Common issues include urinary tract infections, bleeding, and later development of urethral strictures. Hospital stays of a few days and extended catheter times are typical.

Holmium laser enucleation of the prostate (HoLEP) has emerged as a strong alternative, particularly for very large prostates. Compared to TURP in elderly patients, HoLEP significantly cut catheterization time (roughly 22 hours versus 50) and hospital stays (one day versus three).⁹ The trade-off was longer operative times and higher rates of temporary side effects like painful urination and transient incontinence. HoLEP requires specialized training and equipment, so its availability varies by hospital.

The Newest Minimally Invasive Procedures

The treatments generating the most interest right now sit between medications and traditional surgery. They’re performed in outpatient settings, often under light sedation or local anesthesia, and most men go home the same day. Their defining appeal is that they preserve sexual function far better than TURP while still delivering durable symptom relief.

Rezūm (Water Vapor Thermal Therapy)

Rezūm delivers targeted bursts of steam into obstructing prostate tissue. As the vapor condenses, it releases thermal energy at roughly 70 degrees Celsius, causing immediate cell death. Over the following weeks, the dead tissue is reabsorbed by the body, shrinking the prostate and relieving pressure on the urethra.¹⁰ The procedure takes about ten minutes and is typically done in an office setting.

In a single-center study, symptom scores dropped from a baseline average of about 18 to roughly 7 at peak improvement, and urinary flow rate jumped from about 10.5 to nearly 17 mL/s. Nine out of ten patients were able to stop their BPH medications afterward.¹¹ A French prospective study found symptom scores dropped by about 68% at six months and remained roughly 62% lower at one year, with no cases of new erectile dysfunction. The retreatment rate at one year was about 2%.¹² The most common short-term downsides are urinary tract infections and temporary urinary retention during the healing period, when you may need a catheter for a few days to a couple of weeks.

UroLift (Prostatic Urethral Lift)

UroLift takes a mechanical rather than thermal approach. Tiny implants are placed through the urethra to pin back the lobes of the prostate, holding the urethra open the way curtain tie-backs hold drapes apart. No tissue is removed or destroyed. Recovery is fast, and UroLift’s quality-of-life improvements are comparable to TURP while being clearly superior in recovery time and preservation of ejaculatory function.¹³ A study specifically measuring sexual outcomes after UroLift found that erectile function actually improved slightly at all follow-up points, and no patient reported retrograde ejaculation.¹⁴

UroLift works best for prostates under about 80 grams without a prominent median lobe, which limits its candidacy. When studies compare UroLift to Rezūm head to head, Rezūm tends to produce larger improvements in symptom scores: one study found Rezūm patients reported roughly a 58% improvement in symptom scores versus about 45% for UroLift.¹⁵ That said, UroLift’s speed and lack of a mandatory catheter period make it attractive for men who prioritize the fastest possible return to normal activities.

Aquablation (Robotic Waterjet Ablation)

Aquablation is the newest of the three and the most technologically complex. A surgeon uses real-time ultrasound imaging to map the prostate, then a robotic arm delivers a high-pressure waterjet to precisely remove obstructing tissue. Because the mapping and cutting are image-guided and robot-assisted, the procedure can handle very large prostates that would be challenging for other minimally invasive options.

Five-year results from the WATER II trial, which enrolled men with prostates between 80 and 150 mL, showed durable results: symptom scores dropped from an average of about 23 at baseline to roughly 7 at five years, and urinary flow rate nearly doubled. Freedom from needing a repeat procedure at five years was over 96%.¹⁶ Clinical trials consistently show that Aquablation’s primary advantage over TURP is superior preservation of sexual function, with significantly lower rates of ejaculatory dysfunction.¹⁷ A head-to-head comparison with Rezūm in prostates under 80 grams found that both delivered significant, durable improvements in symptoms and quality of life, with Aquablation producing somewhat greater symptom improvement and faster resolution of irritative symptoms, while Rezūm offered shorter operative times and same-day discharge.¹⁸

Prostate Artery Embolization

Prostate artery embolization (PAE) is a procedure performed not by a urologist but by an interventional radiologist. A catheter is threaded through an artery in the wrist or groin to the tiny arteries supplying the prostate, where microscopic beads are injected to block blood flow. Starved of its blood supply, the prostate gradually shrinks. PAE’s effectiveness on both urinary symptoms and flow measurements has been demonstrated across roughly a hundred studies, including several randomized trials.¹⁹

The main selling point of PAE is its extremely low rate of urinary and sexual side effects, including ejaculatory problems. It requires no general anesthesia and no instruments passing through the urethra, which makes it appealing to men who want to avoid anything involving the urinary tract itself. The procedure does have limitations, though. It requires highly specialized vascular anatomy skills, and the prostatic arteries can be tiny and tortuous, making technical success variable. In one study using small embolization beads, while technical catheterization succeeded in all patients, only about 56% were able to remove their urinary catheter at the first follow-up visit.²⁰ PAE typically produces less dramatic improvement in flow rates than surgical options, so it’s generally considered when men either can’t or don’t want to undergo a urological procedure.

How Sexual Function Is Shaping Treatment Choices

A decade ago, conversations about BPH treatment centered almost entirely on how well a procedure unclogged the urethra. Today, preservation of sexual function has become a primary decision driver, and the newer minimally invasive procedures have been evaluated with this outcome front and center. A systematic review and network meta-analysis comparing these treatments found that water vapor thermal therapy (Rezūm) and the prostatic urethral lift (UroLift) were both favored over TURP for ejaculatory function.²¹ Retrograde ejaculation, where semen flows backward into the bladder instead of forward during climax, occurs in a substantial percentage of men after TURP but is rare after Rezūm, UroLift, or Aquablation. For many men, that single difference tips the balance in favor of a newer procedure even if the degree of symptom relief is somewhat less robust than traditional surgery.

Emerging Options Still Building Their Evidence Base

A few treatments are either new enough or niche enough that they haven’t yet been firmly placed in clinical guidelines but are worth knowing about.

The iTIND (temporary implantable nitinol device) is a spring-loaded implant placed in the prostatic urethra under local anesthesia, left in place for five to seven days, then removed. During that time, it reshapes the prostatic channel by applying sustained pressure, creating permanent tissue remodeling. The appeal is that nothing is left behind permanently. Twelve-month data shows improvements in both objective and subjective symptom measures, though the procedure’s formal position in guidelines is still being determined.²²

Intraprostatic Botulinum toxin (Botox) injection has been explored for men who have failed medical therapy and are poor candidates for surgery. Small studies suggest it can safely reduce symptoms in this narrow group, with the transurethral injection route showing the most promise.²³ However, larger trials are needed, and Botox for BPH remains off-label.

The Cost Question

Cost and value matter when weighing these options, and the economics don’t always follow the pattern you’d expect. In a cost-effectiveness analysis comparing PAE to TURP, PAE was cheaper because it avoids an operating theater and requires a shorter hospital stay.²⁴ A separate U.S.-focused analysis estimated PAE at roughly $2,900 versus $6,000 for TURP, with nearly identical quality-of-life-adjusted outcomes over the study period.²⁵

Perhaps the most interesting finding comes from a lifetime cost-effectiveness model comparing medications, UroLift, and Rezūm as initial treatment strategies for moderate to severe BPH. Starting with Rezūm as initial therapy led to the highest quality-adjusted life years and the lowest lifetime cost, at roughly $15,500, compared to about $20,300 for medication followed by Rezūm and about $20,900 for starting with UroLift.²⁶ The implication is that for men with moderate to severe symptoms, jumping straight to a minimally invasive procedure instead of spending years on medication may actually save money over a lifetime, largely because it avoids the accumulating drug costs and the eventual surgical procedure that many men on medication end up needing anyway.

What Your Workup Should Include

Before deciding on any treatment, you should expect a thorough evaluation. Standard workup includes a symptom questionnaire (the International Prostate Symptom Score, or IPSS), a digital rectal exam, urine flow measurement, a PSA blood test, and often an ultrasound to estimate prostate size and check how well your bladder empties. One study found that measuring detrusor wall thickness by ultrasound can detect bladder outlet obstruction more accurately than flow tests, post-void residual volume, or prostate volume alone.²⁷ That said, bladder wall thickness measurement hasn’t become routine everywhere, so ask your urologist whether they use it.

Prostate size matters enormously for treatment selection. UroLift works best for prostates under about 80 grams. Rezūm handles median lobes well, which UroLift traditionally cannot. Aquablation and HoLEP can tackle very large prostates above 100 grams. TURP works reliably for moderate-sized glands but becomes more complex and risky as size increases. Knowing your prostate volume helps narrow the conversation quickly.

When to Consider Skipping Medication Entirely

There’s a growing conversation in urology about whether the standard step-ladder approach, starting with pills and only escalating when they fail, actually serves patients well. The cost-effectiveness data suggesting that early Rezūm beats years of medication is part of this shift. But it’s not just about dollars. Many men tolerate alpha blockers poorly because of dizziness or sexual side effects, and 5-alpha reductase inhibitors can take months to work while causing persistent side effects in a meaningful minority. If your symptoms are moderate to severe and you know you want to preserve sexual function, it’s entirely reasonable to have a direct conversation with your urologist about whether a minimally invasive procedure makes sense as a first step rather than a last resort. The idea that you “have to try pills first” is more a reflection of historical convention than a clinical mandate.